Cancer

Lasers help fight deadly brain tumors

People diagnosed with the aggressive brain cancer glioblastoma face a grim prognosis. Half die within 14 months of diagnosis. Even if initial treatment with surgery, radiation and chemotherapy is successful, such brain tumors typically recur, leaving patients with few options. Now, a research team at Washington University School of Medicine in St. Louis has found

St. Louis is among the world’s leading cities in cancer research

Some 1.75 million new cases of cancer will be diagnosed in the U.S. this year, the National Cancer Institute estimates, and more than 600,000 people will die. But St. Louisans facing cancer often have a fighting chance nowadays, thanks to cutting-edge research and treatment pioneered at local institutions and hospitals. New insights into cancer’s genetic

August 13th, 2018|Categories: Around The State, Cancer|Tags: , , |

Brain tumors occur often in kids with common genetic syndrome

The frequency of brain tumors has been underestimated in children with the common genetic syndrome neurofibromatosis type 1 (NF1), according to a new study. This disorder is characterized by birthmarks on the skin and benign nerve tumors that develop in or on the skin. Brain tumors also are known to occur in children and adults

Late-Stage Preclinical Research Targeting Prostate Cancer Gets Almost $4 Million Support from California’s Stem Cell Agency

A program hoping to supercharge a patient’s own immune system cells to attack and kill a treatment resistant form of prostate cancer was today awarded $3.99 million by the governing Board of the California Institute for Regenerative Medicine (CIRM) In the U.S., prostate cancer is the second most common cause of cancer deaths in men. 

July 23rd, 2018|Categories: Cancer, Disease Specific|Tags: , , , |

Analysis of prostate tumors reveals clues to cancer’s aggressiveness

Using genetic sequencing, scientists have revealed the complete DNA makeup of more than 100 aggressive prostate tumors, pinpointing important genetic errors these deadly tumors have in common. The study lays the foundation for finding new ways to treat prostate cancer, particularly for the most aggressive forms of the disease. The multicenter study, which examined the

July 23rd, 2018|Categories: Around The State, Cancer, Disease Specific|Tags: , |

Brain cancer vaccine effective in some patients

Most people with the deadly brain cancer glioblastoma die less than 18 months after diagnosis. But a multicenter clinical trial of a personalized vaccine that targets the aggressive cancer has indicated improved survival rates for such patients. The study appears May 29 in the Journal of Translational Medicine. The phase three clinical trial included 331

Clinical Trial Targeting Lung Cancer, Plus Promising Osteoporosis and Incontinence Research get Support from Stem Cell Agency

The five-year survival rate for people diagnosed with the most advanced stage of non-small cell lung cancer (NSCLC) is between one and 10 percent. To address this devastating condition, the Board of the California Institute for Regenerative Medicine (CIRM) today voted to invest almost $12 million in a team from UCLA that is pioneering a

Multiple Sclerosis Drug Could Reduce Painful Side Effects of Common Cancer Treatment

Researchers from Saint Louis University School of Medicine have discovered why many multiple myeloma patients experience severe pain when treated with the anticancer drug bortezomib. The study, which was published on April 27 in the Journal of Experimental Medicine, suggests that a drug already approved to treat multiple sclerosis could mitigate this effect and allow myeloma